Metagenomi Therapeutics (MGX) FCF Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly FCF Margin of 1706.65% for Q1 2026, down 114620.0% year-over-year from N/an in Q1 2025, and down 182.46% quarter-over-quarter from 604.22% in Q4 2025.
Metagenomi Therapeutics (MGX) FCF Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported FCF Margin for 4 consecutive years, with 1706.65% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 114620.0% year-over-year to 1706.65%; the TTM figure through Mar 2026 stood at 392.44% (down 16035.0% YoY), while the FY2025 annual figure was 354.88%, down 14036.0% from the prior year.
- FCF Margin eased to 1706.65% in Q1 2026 per MGX's latest filing, from 604.22% in the prior quarter.
- Across five years, FCF Margin topped out at 106.08% in Q4 2023 and bottomed at 1706.65% in Q1 2026.
- Historically, FCF Margin has averaged 395.53% across 4 years, with a median of 258.98% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin surged 13406 bps — and 2026, when it tumbled 114620 bps.
- Metagenomi Therapeutics' FCF Margin stood at 106.08% in 2023, then plunged by 161 bps to 276.78% in 2024, then plunged by 118 bps to 604.22% in 2025, then sank by 182 bps to 1706.65% in 2026.
- Business Quant data shows MGX's FCF Margin at 1706.65% in Q1 2026, 604.22% in Q4 2025, and 246.3% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,706.65% |
| Dec 31, 2025 | -604.22% |
| Sep 30, 2025 | -246.30% |
| Jun 30, 2025 | -251.12% |
| Mar 31, 2025 | -560.46% |
| Dec 31, 2024 | -276.78% |
| Sep 30, 2024 | -246.05% |
| Jun 30, 2024 | -134.84% |
| Mar 31, 2024 | -271.24% |
| Dec 31, 2023 | -106.08% |
| Sep 30, 2023 | -210.22% |
| Jun 30, 2023 | -268.90% |
| Mar 31, 2023 | -258.98% |